Nalu Bio, a San Francisco, CA-based producer of chemistry-based cannabinoids, raised $12M in Series A funding.
The round was led by Intrinsic Capital Partners, with participation from Flybridge Capital Partners, Portfolia Active Aging & Longevity Fund, Bonaventure Equity, L37 Ventures, Golden Seeds, Sacramento Angels, Brown Angel Group, and Axial Venture.
The company intends to use the funds to accelerate growth and scale production of cannabinoids for consumer products and therapeutics.
Founded in 2019 and led by CEO Caitlyn Krebs, Nalu Bio is a biotech company creating a category of chemistry-based cannabinoids (e.g., CBD, THCV, CBN, CBC, CBG) for the consumer and pharmaceutical markets. The company’s platform generates molecularly identical versions of naturally occurring cannabinoids for use in consumer products and therapeutics that are sustainable and completely free from contaminants found in hemp-extracted cannabinoids.
FinSMEs
28/02/2023